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Antidepressant-Like Eﬀect of Ferulic Acid via Promotion
of Energy Metabolism Activity
Kazunori Sasaki, Nozomu Iwata, Farhana Ferdousi, and Hiroko Isoda*
Scope: Ferulic acid (FA), a natural phenolic phytochemical abundantly
present in whole grains, herbs, and dried fruits, exhibits anti-inﬂammatory,
antioxidant, and neuroprotective eﬀects. In the present study, the
antidepressant-like eﬀects of FA in male ICR mice using tail suspension
test (TST) are investigated and its molecular mechanisms are
explored.
Methods and Results: Oral administration of FA at a dose of 5 mg kg–1 for
7 days signiﬁcantly reduces immobility of mice compared to
vehicle-administered control group. Microarray and real-time PCR analyses
reveal that FA upregulates the expression of several genes associated with cell
survival and proliferation, energy metabolism, and dopamine synthesis in
mice limbic system of brain. Interestingly, it is found that FA, unlike
antidepressant drug bupropion, strongly promotes energy metabolism.
Additionally, FA increases catecholamine (dopamine and noradrenaline),
brain-derived neurotrophic factor, and ATP levels, and decreases glycogen
levels in the limbic system of the mice brain.
Conclusion: The research provides the ﬁrst evidence that FA enhances
energy production, which can be the underlying mechanism of the
antidepressant-like eﬀects of FA observed in this study.
1. Introduction
Various sources of stress, such as mental, chemical, structural,
and environmental are constantly increasing in modern soci-
eties. These types of stress, as well as chronic stress, may lead
to major depression in humans. Depression is thought to be a
major public health problem globally. Approximately 350 million
people worldwide are aﬀected by depression. It is expected to be
ranked as the second-leading cause of death by 2020.[1] Common
symptoms of depression include emotional disturbance, such
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as feelings of hopelessness and lack
of motivation, and physical symptoms,
such as sleep disturbance, malaise,
and anorexia. Currently, several antide-
pressant drugs are available, such as
monoamine oxidase inhibitors, selective
serotonin reuptake inhibitors, selective
norepinephrine inhibitors.[2] However, a
major limitation of these antidepressants
is side eﬀects such as vomiting, dysuria,
and sexual dysfunction that cannot be
ignored. It is, therefore, a great scientiﬁc
interest to explore new eﬀective, fast-
acting, and well-tolerated drugs for the
treatment of depression.
Recently, natural resources have re-
ceived attention as eﬀective alternatives
in the treatment of depression. Natu-
ral resources are commonly regarded as
safe-to-use because they have far fewer
adverse eﬀects than the synthetic antide-
pressant drugs currently in use.[3] There-
fore, it is preferable to use natural bioac-
tive compounds such as polyphenols for
the treatment of depression and other
mood disorders. In our previous study, we evaluated the
antidepressant-like eﬀect of Cymbopogon schoenanthus extract
(CSE) in two predictive models of depression in mice; tail sus-
pension test (TST) and forced swimming test. CSE treatment de-
creased immobility time of mice in both models. The eﬀect of
CSE on animal behavior was concordant with a signiﬁcant re-
duction of corticosterone in serum and upregulation of neuro-
transmitters such as dopamine, adrenaline, and noradrenaline
levels in the cerebral cortex of mice.[4] We also analyzed ac-
tive compounds in CSE using HPLC analysis, which identiﬁed
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several active compounds in CSE such as gallic acid, quercetin-3-
rhamnoside, and ferulic acid (FA). In particular, FA is the most
abundant polyphenol in CSE composing up to 10% of the total
phenolic constituent.[4]
FA is a natural polyphenol (4-hydroxy-3-methoxycinnamic
acid), commonly found in food sources such as rice, wheat, bar-
ley, oranges, coﬀee, apples, and peanuts.[5] In addition, FA is
also categorized as a caﬀeoylquinic acid (CQA) derivative. Pre-
viously, we reported that 3,5-diCQA[6] and CQA derivatives from
purple sweet potato extract[7] had neuroprotective activities. An-
other CQA derivative rosmarinic acid (RA) showed antidepres-
sant activity.[8,9] Therefore, FA, as a member of the family of
CQA derivatives, is considered to have potential antidepressant-
like activity. In fact, Lenzi et al. has demonstrated that FA ex-
erts antidepressant-like eﬀects throughmodulation of the antiox-
idant defense system.[10] Another recent study has reported that
the antidepressant-like eﬀects of FA observed in epileptic ani-
mal model were mediated by its anti-inﬂammatory properties.[11]
However, the proposed mechanisms of antidepressant activity of
FA may act in a complementary manner to exert acute changes
necessary for antidepressant behavioral actions, and thus, are
not suﬃcient to explain themolecular mechanism underlying its
antidepressant-like eﬀects.
In the present study, we evaluated the antidepressant-like ef-
fect of FA in ICRmice using TST, an animalmodel of depression.
DNA microarray and real-time PCR analyses were performed
to examine the changes in gene expression in the limbic sys-
tem of mice brain. Furthermore, the current research focuses
on the modulation of catecholamine, corticosterone, and brain-
derived neurotrophic factor (BDNF), and energy metabolism for
an understanding of the molecular mechanism underlying the
antidepressant-like eﬀect of FA.
2. Experimental Section
2.1. Preparation of FA
FA was purchased from FUJIFILMWako Pure Chemical Corpo-
ration. (Tokyo, Japan). FA was dissolved in 99.5% of methanol
(stock solution of FA). The stock solution of FA was dissolved in
drinking water and was orally administered at a concentration of
5 mg kg–1 body weight.
2.2. Animals and FA Administration in ICR Mice
Three-week-old male ICR mice (purchased from the Japan
Charles River, Yokohama, Japan) were used for the in vivo ex-
periment for evaluation of the antidepressant-like activity. All
mice were lodged individually and allowed to acclimate to the
laboratory conditions for 7 days under controlled temperature
(21–23 °C) and light conditions (light:dark 12:12 h) with free ac-
cess to food and water. This animal experiment was approved
by the Ethics Animal Care andUse Committee of theUniversity
of Tsukuba (16-042).
Following acclimatization to laboratory conditions, mice were
randomly divided into three groups: vehicle-treated group (n =
7), bupropion-treated group (n= 7), and FA-treated group (n= 7).
FA (5 mg kg–1) was mixed with drinking water and then directly
administered by oral gavage with a feeding tube and syringe ev-
ery day for 7 days. Previously, we performed several animal ex-
periments using CQA derivatives such as 3,5-diCQA,[6] RA,[9] and
3,4,5-triCQA.[12] These CQA derivatives showed neuronal activity
at the following concentrations: 3,5-diCQA at 6.7mg kg–1; RA at 5
and 10mg kg–1; and 3,4,5-triCQA at 5mg kg–1. Considering these
previous studies, we set the concentration of FA to 5 mg kg–1.
And ﬁnal concentration of methanol in the FA-mixed water was
0.1%. An equal volume of 0.1% methanol water was adminis-
tered to the vehicle-administration group. Bupropion (serotonin
and noradrenaline reuptake inhibitor; DNRI; FUJIFILM Wako
Pure Chemical Corporation. Tokyo, Japan) was used as a positive
control. It was dissolved in distilled water and orally administered
tomice at a volume of 20mg kg–1 body weight, as reported in pre-
vious study.[9]
2.3. Tail Suspension Test
TST was performed 60 min after oral administration of FA as
described previously.[9] Brieﬂy, the mice were held by the tail at
10 mm distance from the tip of the clamp (white box 30 × 15
× 50 cm (L × W × H)) with 30 cm headspace from the bottom
of the box, which had minimal background noise. All mice were
suspended for 6 min in each session and the immobility period
was recorded in the last 4 min of the test. Mice were considered
to be immobile only when they were passive and completely sta-
tionary. Immobility in the TST is assumed to reﬂect behavioral
despair in clinical depression in humans.
2.4. RNA Isolation from Mouse Brain and DNA Microarray
Analysis
After the last TST, all mice were sacriﬁced by cervical dislocation.
The brain tissues were isolated, washed with ice-cold PBS, and
immediately immersed in liquid nitrogen. As previous studies
have pointed out the functional and structural alterations in the
limbic area, including cerebral cortex and amygdala, in mouse
models of depression[9] and in adult patients with major depres-
sive disorder,[13,14] the limbic area of mice brain was focused to
determine the mechanisms of anti-depressant-like eﬀects of FA.
The entire limbic area of the mouse brain containing the cortex,
hippocampus, and amygdale was quickly dissected on ice and
was minced for RNA extraction. Total RNA was puriﬁed from
cerebral tissue using the ISOGEN kit (Nippon Gene Co. Ltd.,
Tokyo, Japan) following the manufacturer’s instructions as re-
ported previously.[15] Total RNA was quantiﬁed and assessed for
quality with NanoDrop 2000 spectrophotometer (Thermo SCI-
ENTIFIC, Wilmington, DE, USA).
DNA microarray analysis was performed as reported
previously.[15] Double-stranded cDNA was synthesized from
100 ng of total RNA with the GeneAtlas 3′ IVT Express Kit
(Aﬀymetrix Inc., Santa Clara, CA, USA). Biotin-labeled ampli-
ﬁed RNA (aRNA) was synthesized by transcription using the
GeneChip 3′ IVT Express Kit (Aﬀymetrix Inc., Santa Clara,
CA, USA). Puriﬁed aRNA (9.4 µg) was fragmented using the
GeneAtlas 3′ IVT Express Kit and was hybridized for 16 h at
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45 °C using GeneChip MG-430 PM microarray (Aﬀymetrix
Inc., Santa Clara, CA, USA). The chip was washed and stained
in the Gene Atlas Fluidics Station 400 (Aﬀymetrix Inc., Santa
Clara, CA, USA) and the resulting image was scanned using the
GeneAtlas Imaging Station (Aﬀymetrix Inc., Santa Clara, CA,
USA). The raw data was normalized using the Aﬀymetrix expres-
sion console (http://www.aﬀymetrix.com). Subsequent analysis
of the gene expression data was carried out using an online data
mining tool DAVID (Database for Annotation, Visualization
and Integrated Discovery, v6.8, National Institute of Allergy and
Infectious Diseases). Compared with the control (vehicle-treated
group), the fold-change in gene expression in the bupropion- or
FA-treated group was calculated and converted to linear data.
2.5. Real-Time PCR
On the basis of ﬁndings from microarray analysis, reverse-
transcription reactions were carried out with the SuperScript III
Reverse Transcriptase kit (Invitrogen, Carlsbad, CA, USA) ac-
cording to the manufacturer’s instructions. One microgram of
total RNA template solution, 10 mm dNTP (Invitrogen, Carls-
bad, CA, USA), Oligo (dT)12-18 primer (Invitrogen, Carlsbad,
CA, USA), and UltraPure DNase/RNase-Free Distilled Water
(Gibco, USA) were mixed and incubated at 65 °C for 5 min
and chilled at 4 °C for 1 min. After adding 5× Reverse Tran-
scriptase buﬀer, 0.1 m DTT, Reverse Transcriptase, and RNase-
OUT (Invitrogen, Carlsbad, CA, USA), the solution was incu-
bated at 42 °C for 60 min, then at 70 °C for 10 min. The
synthesized complementary DNA (cDNA) solution was quanti-
ﬁed using the Nanodrop 2000 spectrophotometer (Thermo SCI-
ENTIFIC, Wilmington, DE, USA) and stored at –20 °C until
use. For the transcript quantiﬁcation, the TaqMan real-time RT-
PCR ampliﬁcation reactions were performed using the Applied
Biosystems 7500 Fast Real-Time System (Applied Biosystems,
Foster City, CA, USA). All primers and the TaqMan Universal
PCR Master Mix were obtained from Applied Biosystems. Spe-
ciﬁc primers for beta actin (Actb) (Mm02619580_s1), hexokinase
(Hk) (Mm02526975_g1), glyoxalase 1 (Glo1) (Mm00844954_s1),
pyruvate kinase (Pk) (Mm00834102_gH), 3-phosphoglycerate
dehydrogenase (Phgdh) (Mm01623589_g1), pyruvate dehydro-
genase kinase, isoenzyme 4 (Pdk4) (Mm01166879_m1), pyru-
vate carboxylase (Pc) (Mm00500992_m1), tyrosine hydroxy-
lase (Th) (Mm004427557_m1), and dopa decarboxylase (Ddc)
(Mm00516688_m1) were used. Ampliﬁcation was performed in
a ﬁnal volume of 20 µL using 9 µL of cDNA solution (containing
100 ng of cDNA), 1 µL of each corresponding primer, and 10 µL
of TaqMan Gene Expression Master Mix. The thermal cycler pro-
gramwas set as 50 °C for 2 min and 95 °C for 10min, followed by
45 cycles of PCR (95 °C, 15 s; 60 °C, 60 s). Results were obtained
from three independent experiments, and the mRNA levels of all
genes were normalized using Actb as an internal control.
2.6. Dopamine and Noradrenaline Levels in Mice Brain
Dopamine and noradrenaline levels in the limbic area of mice
brains were measured using a commercial ELISA kit based on
the sandwich principle (ImmuSmol, inc., Pessac, France). Brieﬂy,
100 mg of the limbic area was isolated from brain tissue and
homogenized in radioimmunoprecipitation assay (RIPA) buﬀer
with protease inhibitor (Santa Cruz Biotechnology, inc., Tokyo,
Japan). After centrifugation (1000× g, 20min), 50 µL supernatant
or 10 µL standards were used for catecholamine extraction, acy-
lation, and determination followingmanufacturer’s instructions.
After optimal color development, the reaction was stopped and
the absorbance was recorded at 450 nm. Dopamine and nora-
drenaline levels were computed by correcting the protein con-
centration. Protein concentration was determined using the 2D
Quant kit (GE Healthcare Inc., Tokyo, Japan) and the data were
expressed as ng µg–1 protein.
2.7. BDNF Level in Mice Brain
BDNF levels in the brain were measured by ELISA kit (R&D Sys-
tems, Inc., Minneapolis, USA) in accordance with the manufac-
turer’s instructions. Brieﬂy, 100 mg of the limbic area was iso-
lated from brain tissue and homogenized in RIPA buﬀer with
protease inhibitor (Santa Cruz Biotechnology, Inc., Tokyo, Japan).
After centrifugation (1000 × g, 20 min), the supernatants or stan-
dards were used to determine the BNDF levels in brain. After the
treatment of BNDF antibody, a second incubation was performed
with streptavidin–horseradish peroxidase conjugate solution for
60 min. After addition of substrate and stop solution, BDNF lev-
els were determined by absorbance at 450 nm. The BDNF levels
were normalized to the protein concentration determined with
the 2D Quant kit (GE Healthcare Inc.). The data were expressed
as ng µg–1 protein.
2.8. Measurement of Brain Glycogen Levels
Biochemical quantiﬁcation of glycogen was performed using
commercial glycogen assay kit (BioVision Inc., Milpitas USA).
After homogenization of the limbic area of mice brain, the ho-
mogenates were centrifuged (1000 × g, 20 min) and the super-
natant was collected. The supernatant of samples or glycogen
standards were transferred to a 96-well plate, followed by incu-
bation with 1 µL hydrolysis enzymemix for 30 min. The samples
were incubated with 1 µL development enzyme mix and 0.3 µL
OxiRed probe for 30 min at room temperature. The absorbance
of samples was measured by a microplate reader (405 nm). The
glycogen concentration was then calculated based on a calibra-
tion curve obtained by the glycogen standard. Protein concentra-
tion was estimated using the 2D Quant kit (GE Healthcare Inc.)
and the data were expressed as ng µg–1 protein.
2.9. Measurement of Brain ATP Levels
ATP levels in the cerebrum tissues were measured using a com-
mercial glycogen assay kit (BioVision Inc., Milpitas, USA). A
small amount (100 mg) of the limbic area of the brain was ho-
mogenized with 1mL RIPA buﬀer with protease inhibitor (Santa
Cruz Biotechnology, Inc., Tokyo, Japan). After centrifugation
(1000 × g, 20 min), the supernatant or ATP standard was trans-
ferred to a 96-well plate. The samples were incubated with 1 µL
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development enzyme mix and 0.3 µL OxiRed probe for 30 min
at room temperature. The absorbance of each sample was mea-
sured by a microplate reader (405 nm). Glycogen concentration
was then calculated based on the calibration curve obtained by
the ATP standard. Protein concentration was estimated using the
2D Quant kit (GE Healthcare Inc.) and the data were expressed
as ng µg–1 protein.
2.10. Corticosterone Level in Mice Serum
Corticosterone levels in the serum were measured using Corti-
costerone ELISA kit (Proteintech Inc., Tokyo, Japan). After 24
h of incubation at 4 °C, the blood was centrifuged at 1000 × g
for 30 min to collect the serum and was immediately stored at
−20 °C until use. Serum samples or standards (10 µL) were used
for corticosterone determination according to manufacturer’s in-
structions. When optimal blue color density developed, the re-
action was stopped and the absorbance was recorded at 450 nm.
The level of serum corticosterone was calculated using a standard
curve. All samples were subjected to single assay and the results
were expressed in ng mL–1.
2.11. Statistical Analysis
Results are expressed as mean ± SEM. Immobility time in
TST was compared between control and treatment groups us-
ing two-way ANOVA followed by post hoc Ryan–Einot–Gabriel–
Welsch multiple range test. One-way ANOVA followed by Ryan–
Einot–Gabriel–Welschmultiple range test was also carried out. A
p-value of <0.05 was considered statistically signiﬁcant.
3. Results
3.1. FA Reverses depressive-like Behavior Induced by TST
To determine whether FA has antidepressant-like activity, its ef-
fect on TST-induced stress in mice was investigated. We found
that vehicle-treated group displayed a signiﬁcant increase in im-
mobility time in TST (35.5 ± 26.9, 57.4 ± 13.7, 77.8 ± 35.3,
91.5 ± 26.7, 108.1 ± 18.0, 112.9 ± 28.4, and 114.4 ± 22.5 s, re-
spectively; Figure 1A). On the other hand, FA administration
(5 mg kg–1) caused a decrease in the immobility time in the TST
(40.1 ± 13.3, 47.1 ± 19.3, 55.0 ± 27.1, 50.0 ± 24.8, 46.0 ± 20.8,
46.9± 12.1, and 53.2± 23.1 s, respectively). The immobility times
of the bupropion-treated group (20mg kg–1), as a positive control,
also showed a decrease (42.5 ± 25.9, 44.7 ± 18.7, 51.8 ± 20.4,
39.4 ± 9.4, 36.4 ± 20.8, 40.1 ± 13.1, and 40.2 ± 14.7 s, respec-
tively) during TST.
Interestingly, on day 7, the FA-administered group (53.2± 23.1
s) showed almost the same decrease in immobility time as the
bupropion-administered group (40.2 ± 14.7 s). Treatment with
FA and bupropion resulted in twofold reduction of the average
immobility time compared with that of the vehicle-administered
group (p < 0.01 vs control; Figure 1B).
Figure 1. Eﬀects of administration of ferulic acid (FA) on immobility times
in the tail suspension test (TST). Mice were orally-administered daily with
vehicle (0.1%methanol water), bupropion (20mg kg–1), or FA (5mg kg–1)
for 7 consecutive days and subjected to TST 60 min after sample adminis-
tration. The immobility time during the ﬁnal 4 min of a 6-min total session
was measured. TST immobility time measured for each group. Data rep-
resent the mean ± SEM (n = 7). **p < 0.01 versus control group.
3.2. FA Upregulated Energy Metabolism-, Cell Proliferation-, and
Dopaminergic Synthesis-Related Signaling Pathway Genes
To evaluate the molecular mechanism of the antidepressant-like
eﬀect of FA, we performed DNAmicroarray analysis of ICRmice
cerebrum to investigate changes in gene expression.
As shown in Table 1, 16 genes were upregulated in the FA-
treated group to the vehicle-treated group. These genes were
functionally classiﬁed into three groups: energy metabolism, cell
survival and proliferation, and dopamine synthesis (Table 1).
More speciﬁcally, FA treatment induced the expression of
energy metabolism signaling-related genes, namely glyoxalase
1 (Glo1), aldolase C, fructose-bisphosphate (Aldoc), pyruvate
kinase (Pk), phosphoglucomutase 2 (Pgm2), 3-phosphoglycerate
dehydrogenase (Phgdh), isocitrate dehydrogenase 3 (NAD+)
alpha (Idh3a), pyruvate dehydrogenase kinase, isoenzyme 4
(Pdk4), succinate dehydrogenase complex, subunit A (Sdha),
ubiquinol-cytochrome c reductase core protein 1 (Uqcrc1), and
NADH dehydrogenase (ubiquinone) 1 alpha/beta subcomplex
1 (Ndufab1). FA also increased several gene expressions re-
lated to cell survival and proliferation signaling such as IFN
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Table 1. Expression changes of cell survival and proliferation-, energy metabolism-, dopamine synthesis-related genes regulated by FA.
Gene title Gene
symbol
Bupropion Ferulic
acid
Function
IFN (𝛼 and 𝛽) receptor 1 Ifnar1 1.07 1.20 Cell survival and proliferation
Serum/glucocorticoid regulated kinase 3 Sgk3 1.03 1.21
Phosphatase and tensin homolog Pten 1.21 1.51
Serum/glucocorticoid regulated kinase 1 Sgk1 1.04 1.53
Glyoxalase 1 Glo1 0.89 1.43 Energy metabolism (glycolysis)
Aldolase c, fructose-bisphosphate Aldoc 1.13 1.35
Pyruvate kinase Pk 1.12 1.37
Phosphoglucomutase Pgm 0.98 1.21
3-Phosphoglycerate dehydrogenase Phgdh 1.06 1.42
Isocitrate dehydrogenase 3 (NAD+) alpha Idh3a 1.18 1.23 Energy metabolism (TCA cycle)
Pyruvate dehydrogenase kinase, isoenzyme 4 Pdk4 1.18 1.33
Succinate dehydrogenase complex, subunit A, ﬂavoprotein (Fp) Sdha 1.05 1.21 Energy metabolism (electron transport chain)
Ubiquinol-cytochrome c reductase core protein 1 Uqcrc1 1.06 1.21
NADH dehydrogenase (ubiquinone) 1, alpha/beta subcomplex, 1 Ndufab1 1.10 1.27
Dopa decarboxylase Ddc 0.52 1.30 Dopamine synthesis
Protein phosphatase 1, regulatory (inhibitor) subunit 1B Ppp1r1b 2.43 1.59
(𝛼 and 𝛽) receptor 1 (Ifnar1), serum/glucocorticoid regulated
kinase 3 (Sgk3), phosphatase and tensin homolog (Pten), and
serum/glucocorticoid regulated kinase 1 (Sgk1). Moreover, FA
increased the expression of several genes related to dopamin-
ergic synthesis signaling pathways such as dopa decarboxylase
(Ddc) and protein phosphatase 1, regulatory (inhibitor) subunit
1B (Ppp1r1b). However, the bupropion-treated mice did not
upregulate the genes related to energy metabolism.
3.3. Eﬀects of FA on the Gene Expression of Energy Metabolism-
and Dopamine Synthesis-Related Mediators
As our microarray results indicated, FA aﬀected the energy
metabolism-, cell survival and proliferation-, and dopamine
synthesis-related genes expression in mouse brain. Especially,
upregulation of energy metabolism-related genes was character-
istic in the FA-administrated mice. Therefore, the gene expres-
sion levels of Glo1, Pk, Phgdh, and Pdk4, which are related to
energy metabolism, were further evaluated in the brains of FA-
administratedmice. Oral administrationwith FA signiﬁcantly in-
creased gene expression levels of Glo1, Pk, Phgdh, and Pdk4 up
to 154.0%, 148.4%, 139.3%, and 235.9%, respectively (Figure 2).
In addition, we also evaluated gene expression levels of hexoki-
nase (Hk), rate-limiting enzymes of the glycolysis and pyruvate
carboxylase (Pc), and tricarboxylic acid (TCA) cycle. We found
upregulation of Hk and Pc by 125.3% and 259.3%, respectively
(Figure 2). Moreover, tyrosine hydroxylase (Th), the rate-
limiting enzyme in the dopamine synthesis, and Ddc, dopamine
synthesis-related genes, were signiﬁcantly increased to 385.1%
and 149.9% in mouse brains treated with FA (Figure 3).
Bupropion treatment also signiﬁcantly upregulated (p < 0.01)
Th and Ddc expression by 400.0% and 110.9% compared to the
control group (Figure 3). However, the gene expressions of Glo1,
Pk, Phgdh, Pdk4, Hk, and Pc were much lesser in the bupropion-
treated group compared to those of in the FA-treated group
(70.8%, 125.1%, 113.4%, 164.2%, 76.2%, and 95.8%, respectively;
Figure 2).
3.4. Eﬀects of FA on Dopamine, Noradrenaline, and BDNF
Levels in the Limbic System of Mice Brain
As shown in Figure 4, the oral administration of FA signiﬁ-
cantly elevated the contents of dopamine (45.3 ± 5.4 ng µg–1
protein), noradrenaline (4.0 ± 0.3 ng µg–1 protein), and BDNF
(41.5 ± 1.9 ng µg–1 protein) levels in the limbic system of the
mice brain compared with those of in the vehicle-treated con-
trol group (21.4 ± 4.7 ng µg–1 protein, 2.8 ± 0.3 ng µg–1 protein,
31.3± 1.0 ng µg–1 protein, respectively; p< 0.01). The bupropion-
treated group also showed signiﬁcantly increased dopamine
(50.8 ± 8.1 ng µg–1 protein), noradrenaline (4.6 ± 0.4 ng µg–1
protein), and BDNF (47.0 ± 4.2 ng µg–1 protein) levels in the
mice brain compared with those of in the vehicle-treated group
(p < 0.01). However, there was no signiﬁcant diﬀerence in these
parameters between FA-and bupropion-treated groups.
3.5. Eﬀects of FA on Glycogen and ATP Levels in the Limbic
System of Mice
Brain glycogen level was signiﬁcantly decreased (p < 0.01) in FA-
treated group (6.9 ± 0.4 ng µg–1 protein) compared with that
of in vehicle-treated group (12.4 ± 0.5 ng µg–1 protein). Bupro-
pion treatment also signiﬁcantly decreased brain glycogen level
(6.9± 0.4 ng µg–1 protein) compared with control group (p< 0.01;
Figure 5A).
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Figure 2. Eﬀect of the administration of ferulic acid (FA) on mRNA expression of energy metabolism-related genes in mice brain limbic system. Gene
expression level of A)Hk, B) Glo1, C) Pk, D) Phgdh, E) Pdk4, and F) Pc, and were normalized to Actb level and expressed as a ratio relative to the control
group. Each bar represents the mean ± SEM (n = 7 independent experiments). *p < 0.05; **p < 0.01 treatment versus control group.
Similarly, ATP level in the FA-administered (373.7 ±
36.9 pg µg–1 protein) and bupropion-administered (252.2 ±
27.3 pg µg–1 protein) groups was increased signiﬁcantly (p< 0.01)
compared with that of in the vehicle-administered group
(100.3 ± 2.2 pg µg–1 protein). Interestingly, the changes in glyco-
gen and ATP levels were much higher in the FA-administered
group compared to those of in bupropion-administered group.
3.6. Eﬀects of FA on Serum Corticosterone Level in Mice Blood
Serum
As shown in Figure 6, FA-administered group elicited a sig-
niﬁcant reduction (p < 0.01) in serum corticosterone level in
mice (105.1 ± 10.9 ng mL–1) compared to vehicle-administered
group (243.1 ± 21.6 ng mL–1). Similar eﬀect was observed in the
bupropion-administered group (104.4 ± 8.5 ng mL–1, P < 0.01 vs
control). Both FA and bupropion showed similar reduction in the
TST-induced increased level of serum corticosterone.
4. Discussion
The rapidly growing functional food industrymay ﬁnd promising
remedies to overcome this problem. In the present study, we in-
vestigated the antidepressant-like eﬀects of FA through an acute
mouse behavioral model of despair task TST. The TST has been
widely used as an animal model to evaluate the pharmacologi-
cal antidepressant activity.[16] The present study shows that FA,
when administered orally at the dose of 5 mg kg–1 body weight,
eﬀectively reduced immobility time in the TST-subjected mice.
Moreover, FA treatment signiﬁcantly decreased serum corticos-
terone levels, in a similar way to bupropion, which is a commer-
cial anti-depressant drug. Also, our study demonstrated that FA
signiﬁcantly increased the protein-expression level of BDNF in
mice brain, the predictive biomarker of depression. All together
the decrease of the immobility time in the TST,[17] the decrease
of serum corticosterone levels,[9] and the increase of brain BDNF
levels[18] can be considered as an index for antidepressant eﬀect,
suggesting the antidepressant-like eﬀect of FAs.
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Figure 3. Eﬀect of the administration of ferulic acid (FA) on mRNA ex-
pression of dopamine synthesis-related genes inmice brain limbic system.
Gene expression level of A) Th and B) Ddc were normalized to Actb level
and expressed as a ratio relative to the control group. Each bar represents
the mean ± SEM (n = 7 independent experiments). *p < 0.05, **p < 0.01
treatment versus control group.
Previous studies reported early dysregulation ofmitochondrial
functions as a symptom of major depression in adult patients.[19]
Previous evidences showed that mitochondrial function and en-
ergy metabolism are important for social behavior.[20] In our mi-
croarray results, we reported an increase in the expression of
Glo1, Aldoc, Pk, Pgm, and Phgdh genes, which are all involved
in glycolysis (Table 1). Moreover, we also conﬁrmed the upregu-
lation of IDH3a, Pdk4, Sdha, Uqcrc1, and Ndufab in mice brains
treated with FA, which are related to the TCA cycle and electron
transport chain in mitochondria (Table 1). In addition, FA treat-
ment signiﬁcantly increased the gene expression levels ofHk and
Pc, the rate-limiting enzymes of the glycolysis and TCA cycle. It
was previously reported that there were signiﬁcant loss of mi-
tochondrial ATP production and reduction in mitochondrial en-
zyme ratio in the patients with major depression.[21] This present
study shows that FA treatment increased the ATP level in the lim-
bic area of the brain of ICRmice. Therefore, these results suggest
that the ATP production in FA-treated cells was increased due
to activation of genes related to energy metabolism. Despite the
implication of glucocorticoids in glucose metabolism disorder
and in comorbidity between depression and diabetes, only a few
studies have attempted to determine the role of glycolytic en-
Figure 4. Eﬀect of administration of ferulic acid (FA) on the levels of
the A) dopamine, B) noradrenaline, and C) brain-derived neurotrophic
factor (BDNF) in mice brain limbic system. Mice were administered
orally with vehicle (0.1% methanol water), bupropion (20 mg kg–1 d–1),
or FA (5 mg kg–1 d–1) for 7 days and subjected to TST 60 min after drug
administration. Dopamine, noradrenaline, and BDNF in the brain limbic
system were quantiﬁed using ELISA as detailed in Experimental Section.
Each bar represents the mean ± SD (n = 7). **p < 0.01 treatment versus
control group.
ergy metabolism in any model of depression.[22] Thus, our study
provides the ﬁrst evidence of antidepressant eﬀects via promo-
tion of energy metabolism by FA.
Glycogen, a complex glucose polymer found in the brain
and liver, is usually considered as an energy store. Although
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Figure 5. Eﬀect of administration of ferulic acid (FA) on the levels of A) the
glycogen and B) ATP in mice brain limbic system. Mice were administered
orally with vehicle (0.1% methanol water), bupropion (20 mg kg–1 d–1),
or FA (5 mg kg–1 d–1) for 7 days and subjected to TST 60 min after drug
administration. Glycogen and ATP in the brain limbic system were quan-
tiﬁed using a colorimetric assay kit as detailed in Materials and Method.
Each bar represents the mean ± SD (n = 7). **p < 0.01 treatment versus
control group.
Figure 6. Eﬀects of administration of ferulic acid (FA) on serum corticos-
terone levels in the mice subjected to TST. Mice were administered orally
with vehicle (0.1% methanol water), bupropion (20 mg kg–1 d–1), or FA
(5 mg kg–1 d–1) for 7 days and subjected to TST 60 min after drug admin-
istration. Corticosterone levels in mice blood serum were quantiﬁed using
ELISA as indicated in Experimental Section. Each bar represents the mean
± SD (n = 7). **p < 0.01 treatment versus control group.
brain glycogen is crucial for sustaining neuronal function un-
der conditions of high energetic challenge such as hypoxia or
hypoglycemia,[23,24] glycogen metabolism is profoundly aﬀected
by stress. For example, sleep deprivation decreased the glyco-
gen level in the rat hippocampus,[25] and surgical stress resulted
in the reduction in brain glycogen.[26] In the present study, we
found that administration of bupropion or FA signiﬁcantly de-
creased brain glycogen levels compared with TST-stressed un-
treated mice (vehicle-administered mice). Unlike brain glyco-
gen levels, however, brain ATP levels in bupropion- or FA-
administered mice were signiﬁcantly increased compared with
that of in the TST-stressed mice (vehicle-administrated mice).
Moreover, our results of microarray and real-time PCR showed
FA treatment upregulated the expressions of genes related to
energy metabolism pathways such as glycolysis and TCA cycle.
These results suggested that FA treatment increased brain ATP
levels by promoting brain glycogen metabolism. Generally, ATP
is essential for neuronal activities such as proliferation and dif-
ferentiation. Therefore, promotion of brain ATP levels by FA-
administration is considered to contribute to the activation of
neural functions.
On the other hand, our microarray results showed that FA
upregulated of the gene expression of Ddc and Ppp1r1b, which
are involved in dopaminergic signaling. We also found that
FA upregulated the Th gene expression in mice brains. The
monoamine hypothesis suggested that depressionmay be the re-
sult of dysregulation of monoaminergic neurotransmitters such
as dopamine in the central nervous system. Dopamine is one of
the most abundant monoamine neurotransmitters in the brain
and plays an important role in regulating emotion, motivation,
and cognition.[27,28] Ddc encoding the enzyme aromatic 1-amino
acid decarboxylase, an essential enzyme in various neurotrans-
mitter pathways, is an interesting candidate gene for mental ill-
ness and psychiatric disorders.[29] It has also been reported that
the enzyme encoded by the Ddc gene is required for the syn-
thesis of dopamine, norepinephrine, and serotonin.[30] Ppp1r1b,
which encodes dopamine and cAMP regulatory neuron phos-
phoprotein, is involved in the regulation of dopaminergic and
glutamatergic signaling and in various neurological and psycho-
logical disorders including schizophrenia and depression.[31,32]
Moreover, Th is the rate-limiting enzyme in dopamine synthesis
and is active in its phosphorylated form.[33] Activated Th stimu-
lates the production of dopamine, so Th levels can be used as a
marker for the dopamine production.[34,35] Results obtained from
our study showed that FA treatment increased brain dopamine
and noradrenaline levels suggesting the promoting eﬀect of FA
in dopamine production.
In our previous study, we reported that CQA derivatives pro-
moted energy metabolism through upregulating the genes as-
sociated with glycolysis,[6] TCA cycle,[7] and intracellular ATP
production.[6,36] Moreover, metabolomics analysis showed that
3,5-diCQA and 3,4,5-triCQA exhibited promotion of central
metabolic pathways such as glycolysis and the TCA cycle.[37] In-
terestingly, FA, one of the CQA derivatives, also showed upreg-
ulation of genes related to energy production and induced the
decrease of glycogen and the increase of ATP levels in the lim-
bic area of mice brain in our present work. There are only few
publications to date in PubMed that reported impaired energy
metabolism in major depressive disorder.[38–44] Therefore, our
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current research on the promotion of energy metabolism by FA
may contribute to a new strategy toward a therapeutics for the
treatment of depression.
Taken together, our present research suggests that FA exerts
antidepressant-like eﬀects in an animal model of depression.
Such properties appear to be mediated by enhancement of cell
survival and proliferation, energy metabolism, and dopamine
synthesis in mouse brain. Notably, the energy metabolism-
promoting eﬀects of FA were not observed in the bupropion-
treated group that was used as positive control in this study. These
newly discovered eﬀects of FA may contribute to new strategies
for the treatment of neurodegeneration-induced depression.
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